J. Avasarala

发表

Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis

K. Trinkaus, A. Cross, J. Avasarala, 2003, Multiple sclerosis.

The first 3D printed multiple sclerosis brain: Towards a 3D era in medicine

J. Avasarala, Todd Pietila, T. Pietila, 2017 .

Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest

J. Avasarala, 2017, Neurology.

Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis.

C. McLouth, J. Avasarala, Z. Guduru, 2021, Multiple sclerosis and related disorders.

Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-α-treated primary cultures of human microvascular endothelial cells

J. Avasarala, S. Konduru, 2007, Journal of Molecular Neuroscience.

Is a Neurologist Needed to Diagnose Acute Stroke in the Emergency Department?: Too Many Cooks Might Spoil the Broth.

J. Avasarala, 2016, JAMA neurology.

Letter by Avasarala Regarding Article, "2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association".

J. Avasarala, 2015, Stroke.

Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?

J. Avasarala, Phenu Zachariah, 2015, Journal of the Neurological Sciences.

A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis

M. R. Wall, G. Wolfe, J. Avasarala, 2007, Journal of Molecular Neuroscience.

Multiple sclerosis in US minority populations: Clinical practice insights.

J. Avasarala, 2015, Neurology. Clinical practice.

Inadequacy of clinical trial designs and data to control for the confounding impact of race/ethnicity in response to treatment in multiple sclerosis.

J. Avasarala, 2014, JAMA neurology.

Microarray and miRNA analyses of brain lesions in African- American and Caucasians with multiple sclerosis

S. Chittur, J. Avasarala, M. Kuentzel, 2009 .

Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

J. Avasarala, 2018, Neurology.

Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

Julie R. Jones, J. Avasarala, C. Rogers, 2018, Multiple sclerosis and related disorders.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis

J. Avasarala, 2016, Neurology.

Antibody panels for autoimmune and paraneoplastic disorders: A pandora's box for clinicians.

J. Avasarala, Saurav Das, Sally Mathias, 2022, Multiple sclerosis and related disorders.

Discordant disability data in multiple sclerosis phase 3 studies among sphingosine-1- receptor modulator drugs.

J. Avasarala, 2020, Multiple sclerosis and related disorders.

Approach to Fingolimod‐Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?

J. Avasarala, Sandip Jain, Enrique Urrea-Mendoza, 2017, Journal of clinical pharmacology.

Oligoclonal band number as a marker for prognosis in multiple sclerosis.

A. Cross, J. Avasarala, J. Trotter, 2001, Archives of neurology.

It's Time For Combination Therapies: in Multiple Sclerosis.

J. Avasarala, 2017, Innovations in clinical neuroscience.

Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department.

J. Avasarala, G. Pesola, 2002, The Journal of emergency medicine.

The TOUCH program and natalizumab: Fundamental flaw in patient protection

J. Avasarala, 2016, F1000Research.

The TOUCH program and natalizumab: Fundamental flaw in patient protection.

J. Avasarala, 2015, F1000Research.

The TOUCH program and natalizumab: Fundamental flaw in patient protection

J. Avasarala, 2016, F1000Research.

Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

D. Clifford, A. Cross, B. Siegel, 2003, Multiple sclerosis.

Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity?

J. Avasarala, Phenu Zachariah, B. Turner, 2021, CNS Spectrums.

Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity?

J. Avasarala, Phenu Zachariah, B. Turner, 2021, CNS Spectrums.

FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients

J. Avasarala, 2019, CNS Spectrums.

Surrogate markers in multiple sclerosis.

J. Avasarala, 2001, Archives of neurology.

Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?

J. Avasarala, Naveen Parti, 2018, Front. Neurol..

Stem cell therapies in multiple sclerosis - united we stand, divided we fail

J. Avasarala, 2015 .

Bmc Medical Genomics Microarray Analysis in B Cells among Siblings With/without Ms -role for Transcription Factor Tcf2

S. Chittur, J. Tine, Ajish George, 2022 .

Pleiotropy in FOXC1-attributable phenotypes involves altered ciliation and cilia-dependent signaling

I. MacDonald, O. Lehmann, T. Kume, 2020, bioRxiv.

Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosis

F. Yousuf, J. Avasarala, 2019, CNS Spectrums.

Newer multiple sclerosis drugs and disability scores—are key data analyses missing?

J. Avasarala, 2015, Journal of clinical pharmacology.

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

J. Avasarala, 2004, Neurology.

Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder

J. Avasarala, B. Sokola, Selina Mullins, 2019, CNS Spectrums.

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms.

J. Avasarala, 2017, Innovations in clinical neuroscience.

Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder ?

J. Avasarala, Z. Guduru, J. Gurwell, 2020, Multiple sclerosis and related disorders.

Reader response: Optical coherence tomography for diagnosing optic neuritis: Are we there yet?

J. Avasarala, 2020, Neurology.

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

J. Avasarala, 2017, Drug target insights.

Reader Response: Practice Current: How do you treat neuromyelitis optica?

J. Avasarala, 2018, Neurology. Clinical practice.

Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis.

J. Avasarala, Z. Guduru, E. Miller, 2020, Multiple sclerosis and related disorders.

Analysis of NAMCS data for multiple sclerosis, 1998–2004

S. Feldman, F. Camacho, C. O'Donovan, 2007, BMC medicine.

Clinically isolated syndrome — Rethinking the diagnosis

J. Avasarala, 2015, Journal of the Neurological Sciences.

Cerebrospinal fluid proteomics – work in progress

J. Avasarala, 2008, European journal of neurology.

VAERS‐reported new‐onset seizures following use of COVID‐19 vaccinations as compared to influenza vaccinations

C. McLouth, J. Avasarala, Phenu Zachariah, 2022, British journal of clinical pharmacology.

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

J. Avasarala, 2004, Neurology.

Artificial intelligence extension of the OSCAR‐IB criteria

Thomas E. Wisnewski, Jerry L Prince, J. Schuman, 2021, Annals of clinical and translational neurology.

Neurological Disorders: Course and Treatment

J. Avasarala, Jagannadha R. Avasarala, 2004 .

Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis.

J. Avasarala, S. Konduru, 2005, Journal of molecular neuroscience : MN.

DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?

J. Avasarala, 2018, Drug target insights.

Optimization of acute stroke care in the emergency department: a call for better utilization of healthcare resources amid growing shortage of neurologists in the United States

J. Avasarala, Keith Wesley, 2017, CNS Spectrums.

Bmc Medical Genomics Microarray Analysis in B Cells among Siblings With/without Ms -role for Transcription Factor Tcf2

S. Chittur, J. Tine, Ajish George, 2022 .

Neurological Disorders: Course and Treatment

J. Avasarala, 2004 .

Preliminary findings of a ‘test bundle’ to accelerate the diagnosis of MS and NMOSD following Optic Neuritis

J. Avasarala, Christopher J McLouth, Abusamra Khawla, 2024, Multiple Sclerosis and Related Disorders.